Novel CRISPR enzyme could expand the range of targets for gene therapy
The novel CRISPR-CasΦ enzyme, isolated from bacteriophages, can target a wider range of genetic sequences, say the researchers.
List view / Grid view
The novel CRISPR-CasΦ enzyme, isolated from bacteriophages, can target a wider range of genetic sequences, say the researchers.
Learn how one lab is saving time, improving traceability, and standardising protocols by using connected tools and recording all workflows digitally.
Researchers reveal drugs inhibiting Neuropilin-1 (NRP1), a protein expressed on T cells, could improve the efficacy of immunotherapies.
Researchers capitalised on novel sequencing technologies to produce the first end-to-end DNA sequence of the X chromosome.
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
Researchers reveal the Vav3 protein is responsible for the formation of bacterial docking stations in the airway cells which promote the recurrent lung infections seen in Cystic Fibrosis patients.
The proteomic map based on data from 103 patients reveals novel prognostic biomarkers and potential drug targets for lung adenocarcinoma.
Researchers found breast cancer cells reprogrammed natural killer T cells, altering gene expression and receptor expression so they help cancerous metastases spread.
Ophthalmology and engineering combine in a novel nanoparticle-delivered gene therapy approach to treating wet age-related macular degeneration.
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
Researchers isolated monoclonal antibodies from children who has survived infection by EV-D68, the virus linked to acute flaccid myelitis (AFM). These antibodies protected mice against infection.
Scientists reveal eight new molecules, five of which are already US FDA-approved, that can block the polymerase reaction SARS-CoV-2 uses to replicate its genome.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
The team used cryogenic electron microscopy (cryo-EM) to show how the 10E8 antibody interacts with the HIV’s fusion protein to neutralise the virus.